astellas
Leading Light for Life

News Release

May 7, 2007

Adverse Event of FG-2216 for the Treatment of Anemia

Japan, May 7, 2007-Astellas Pharma Inc. ("Astellas"; headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced that in the phase II clinical trial of FG-2216 (development code. Astellas code name: YM 311) for patients in pre-dialysis chronic kidney disease being conducted in the United States by FibroGen, Inc. ("FibroGen"; headquarters: South San Francisco, CA; Chairman, founder and CEO: Thomas B. Neff), there was one case of death by fulminant hepatitis. FG-2216 is a compound for oral anemia treatment for which Astellas has licensed from FibroGen for exclusive development and marketing in Japan and Europe, etc.

FibroGen has reported this case to the FDA and will be discussing with the FDA about the potential cause and the future plan. Astellas, in close collaboration with FiroGen, is now analyzing the detailed information on this case.

FG-2216 is a compound newly discovered and synthesized by FiroGen as a drug to increase the production of endogenous erythropoietin (EPO). At present, recombinant human EPO (rHuEPO) administered by subcutaneous or intravenous injection is the mainstay of treatment for anemia. FG-2216 is expected to meet unmet medical needs as the world's first low-molecular-weight oral drug for the treatment of anemia. In the United States and Europe, FG-2216 is now in phase II for renal anemia pre-dialysis and for renal associated dialysis, respectively. FibroGen and Astellas are now jointly developing this compound.

#######

Contacts for inquiries or additional information
Astellas Pharma Inc. Corporate Communications Tel: +81-3-3244-3201 Fax: +81-3-5201-7473 http://www.astellas.com